专利 已注册

--

Overview

ໜ້ານີ້ສະຫຼຸບ ສິດທິບັດ «--» ຈາກຂໍ້ມູນຈົດທະບຽນເປີດ, ຍື່ນໂດຍ OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "NAUCHNO-TEKHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA "POLYSAN" ໃນວັນທີ 2017-09-07; ສະຖານະ ຈົດທະບຽນແລ້ວ. ຕົວລະບຸ: ເລກທີຄຳຮ້ອງ P/654; ລະຫັດ DIP LAP654; ປະເພດການປົກປ້ອງ Patent - PCT National Phase. ວັນທີສຳຄັນ: ວັນເຜີຍແຜ່ 2025-02-21; ວັນຈົດທະບຽນ/ອະນຸຍາດ 2025-02-20; ວັນໝົດອາຍຸ 2037-09-07. ປະເພດ/ຫ້ອງ: A61K 31/194、A61K 31/455、A61K 31/675、A61K 31/708、A61K 47/02、A61K 47/18、A61K 9/08. ນັກປະດິດ/ນັກອອກແບບ: KOVALENKO, Alexey Leonidovich, PETROV, Andrey Yurievich. ສະຫຼຸບ: The invention relates to chemical and pharmaceutical industry and, in particular, to a. ຂໍ້ມູນເພື່ອອ້າງອີງເທົ່ານັ້ນ ບໍ່ແມ່ນຄຳແນະນຳທາງກົດໝາຍ ຫຼື ໃບຢັ້ງຢືນສິດ.

专利 老挝 DIP

申请号 P/654
申请日期 2017-09-07
注册/授权日 2025-02-20
申请人 OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "NAUCHNO-TEKHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA "POLYSAN"
代理机构 Tilleke & Gibbins Lao Co., Ltd
类别 A61K 31/194 · A61K 31/455 · A61K 31/675 · A61K 31/708 · A61K 47/02 · A61K 47/18 · A61K 9/08

图样

下载

基础信息

类型
专利
申请号
P/654
状态
已注册
申请人
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "NAUCHNO-TEKHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA "POLYSAN"
代理机构
Tilleke & Gibbins Lao Co., Ltd
申请日期
2017-09-07
注册号
P/654
公开/公告日
2025-02-21
注册/授权日
2025-02-20
届满日
2037-09-07
国际分类
A61K 31/194 · A61K 31/455 · A61K 31/675 · A61K 31/708 · A61K 47/02 · A61K 47/18 · A61K 9/08
商品 / 服务

办理流程

根据当前状态动态标注
  1. 提交申请
  2. 形式审查
  3. 实质审查
  4. 公开
  5. 授权

关联分析

LaoBiz 企业数据库联动

摘要

The invention relates to chemical and pharmaceutical industry and, in particular, to a

method for producing a stabilized pharmaceutical composition presented as an aqueous solution

that may be used to obtain an intravenous drug containing succinic acid, nicotinamide, inosine and

riboflavin mononucleotide as the active ingredients and possessing cytoprotective properties.

The invention objective is to develop a method for producing the known stabilized

pharmaceutical composition presented as an aqueous solution that would enable to enhance its

safety in use through the application ofthermal sterilization. The objective is achieved by a method for producing a stabilized pharmaceutical

composition presented as an aqueous solution containing succinic acid, inosine, nicotinamide,

riboflavin mononucleotide sodium as the active ingredients, by way ofdissolving them in water

with subsequent sterile filtratioru wherein, in accordance with the invention, the composition is

supplemented by one or several ofthe pharmaceutically acceptable components as the stabilizing agent to be selected from the goup including sodium hydroxide,

tris(hydroxymethyl)aminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate,

meglumine, up to a stable solution with pH from 6.0 to 8.0, the components' ratio,Tow! being as

follows: succinic acid 5.00-12.50 inosine 1.00-2.40 nicotinamide 0.50- 1.20 riboflavin mononucleotide sodium 0.10-0.24 stabilizing agent 3.21-51.30 water up to 100.00lo, and the solution is subjected to additional thermal sterilization at l00oC with exposure time of8

minutes to I I 6'C with exposure time of 2 minutes.

In a particular embodiment, the objective is achieved by adding sodium hydrocarbonate to the composition as the stabilizing agent, up to a stable solution with pH of 6.0 to 7.0, the

components' ratio,Yowl. being as follows: succinic acid 5'00-12.50 inosine 1.00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24

The invention relates to the chemical and pharmaceutical industry. A method for producing a stabilized pharmaceutical composition in the form of an aqueous solution comprising active ingredients which include succinic acid, inosine, nicotinamide and riboflavin mononucleotide sodium salt, wherein a stabilizing agent is further introduced into the composition as one or more pharmaceutically acceptable ingredients selected from the group consisting of sodium hydroxide, tris-(oxymethyl)aminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate and meglumine to obtain a stable aqueous solution having a pH value in the range of 6.0 to 8.0; the method further comprises a sterilizing filtration of the resulting dissolved composition, and an additional thermal sterilization at temperatures from 100°C and an exposure time of 8 minutes to 116°C and an exposure time of 2 minutes.sodium hydrocarbonate 13.70-17.20 water uP to 100.0%.

Further in particular embodiment, the objective is achieved by additionally introducing

sodium hydrocarbonate to the composition as the stabilizing agent, up to a stable solution with pH

of 6.4 to 7.4, the components' ratio,Towt. being as follows: succinic acid 5.00-12.50 inosine I '00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24 sodium hydrocarbonate 13.70-17.20 water uP to 100.0%.

提交咨询

留下联系方式,顾问将在工作时间内回复。

联系方式 * 点选后填写 · 至少一种
验证码 *
验证码

登录 LaoBiz

使用注册邮箱登录您的账号

或使用

使用 Google 登录

还没有账号?

或使用

使用 Google 注册

已有账号?

该社交账号未提供邮箱,请填写常用邮箱并完成验证后即可登录。